Based on the AKESO INC. O.N. stock forecast from 0 analysts, the average analyst target price for AKESO INC. O.N. is not available over the next 12 months. AKESO INC. O.N.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AKESO INC. O.N. is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, AKESO INC. O.N.’s stock price was EUR 7.35. AKESO INC. O.N.’s stock price has changed by -3.29% over the past week, -1.34% over the past month and +37.38% over the last year.
No recent analyst target price found for AKESO INC. O.N.
No recent average analyst rating found for AKESO INC. O.N.
Company Overview AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China. Read Less
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellu...Read More
Frequently Asked Questions About AKESO INC. O.N. (4RY:F) Stock
Stock Target Advisor's fundamental analysis for AKESO INC. O.N.'s stock is Slightly Bullish .
Unfortunately we do not have enough data on 4RY:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4RY:F's stock to indicate what its average analyst target is.
4RY:F stock's Price/Earning ratio is 23.23.
Our analysis grades 4RY:F stock's Price / Earning ratio at F. This means that 4RY:F stock's Price/Earning ratio is above 61% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4RY:F may be a overvalued for its sector.
The last closing price of 4RY:F's stock was EUR 7.35.
The most recent market capitalization for 4RY:F is EUR 7.24B.
Unfortunately we do not have enough analyst data on 4RY:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AKESO INC. O.N.'s stock.
As per our most recent records AKESO INC. O.N. has 2,815 Employees.
AKESO INC. O.N.'s registered address is No. 6, Shennong Road, Zhongshan, China, 528437.
You can get more information about it from AKESO INC. O.N.'s website at https://www.akesobio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AKESO INC. O.N. (4RY:F) Stock
Stock Target Advisor's fundamental analysis for AKESO INC. O.N.'s stock is Slightly Bullish .
Unfortunately we do not have enough data on 4RY:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4RY:F's stock to indicate what its average analyst target is.
4RY:F stock's Price/Earning ratio is 23.23.
Our analysis grades 4RY:F stock's Price / Earning ratio at F. This means that 4RY:F stock's Price/Earning ratio is above 61% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4RY:F may be a overvalued for its sector.
The last closing price of 4RY:F's stock was EUR 7.35.
The most recent market capitalization for 4RY:F is EUR 7.24B.
Unfortunately we do not have enough analyst data on 4RY:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AKESO INC. O.N.'s stock.
As per our most recent records AKESO INC. O.N. has 2,815 Employees.
AKESO INC. O.N.'s registered address is No. 6, Shennong Road, Zhongshan, China, 528437.
You can get more information about it from AKESO INC. O.N.'s website at https://www.akesobio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4RY:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
